4-N-Dodecyloxyphenol

CAS No. 13037-87-1

4-N-Dodecyloxyphenol( —— )

Catalog No. M36416 CAS No. 13037-87-1

4-N-Dodecyloxyphenol (p-Dodecyloxyphenol) is a compound that can be used as an additive to ferroelectric or ferroelectric liquid crystals or to display the SmC phase and has no chiral groups.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 144 Get Quote
5MG 238 Get Quote
10MG 323 Get Quote
25MG 534 Get Quote
50MG 762 Get Quote
100MG 1035 Get Quote
500MG 2052 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    4-N-Dodecyloxyphenol
  • Note
    Research use only, not for human use.
  • Brief Description
    4-N-Dodecyloxyphenol (p-Dodecyloxyphenol) is a compound that can be used as an additive to ferroelectric or ferroelectric liquid crystals or to display the SmC phase and has no chiral groups.
  • Description
    4-N-Dodecyloxyphenol (p-Dodecyloxyphenol) is a compound that can be used as an additive to ferroelectric or ferroelectric liquid crystals or to display the SmC phase and has no chiral groups.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    13037-87-1
  • Formula Weight
    278.43
  • Molecular Formula
    C18H30O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(CCCCCCCCCCCC)C1=CC=C(O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • threo-7,9,9-Trihydro...

    The herbs of Leucaena leucocephala.

  • N-(2-Chloro-6-methyl...

    N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.

  • Burosumab

    Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.